A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia

NCT03465787 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

210

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: Lurasidone HCL 160 mg
DRUG: Quetiapine XR 600 mg

Sponsor

Bukwang Pharmaceutical